Andrew Leslie Denver

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

SpeeDx Pty Ltd. is a medical diagnostic company focused on the research, development and commercialization of molecular diagnostic detection technologies. It offers various technologies, including MNAzymes, which are multi-component nucleic acid enzymes composed of DNA to be adapted for sensitive and specific multiplexed detection of various target analytes, as well as catalytically modify substrates producing signals to indicate the presence of target; DNAzymes, which are deoxyribozymes or DNA enzymes to catalyze a repertoire of chemical reactions and are used in the sensor/nanotechnology arena, as well as used for human and animal health; and EzyAmp, an isothermal signal amplification cascade that utilizes restriction enzymes. The company was founded by Elisa E. Mokany and Alison V. Todd in 2009 and is headquartered in Eveleigh, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.

Vaxxas Pty Ltd. develops and commercializes needle-free vaccine delivery system solutions. Its flagship products, Nanopatch, consists of an array of thousands of vaccine coated microprojections that perforate into the outer layers of the skin when applied with an applicator device. The tips of Nanopatch's microprojections are coated with a vaccine material and release this material directly to the large numbers of key immune cells immediately below the skin surface. The company was founded by Mark Kendall in August 2011 and is headquartered in Sydney, Australia.